Abstract
The aim of this study is to evaluate the role of IL28B rs12979860 polymorphism on pegylated interferon (peg IFN) and oral antiviral treatment in chronic hepatitis B (CHB) patients and to investigate the relationship between the severities of illness with this polymorphism. 74 CHB patients who are received treatment, 61 asymptomatic carriers and 40 healthy controls were recruited in this study. Genomic DNA of controls and patients were extracted from whole blood using High Pure PCR Template Preparation Kit (Roche, Mannheim, Germany) according to the manufacturer’s instructions and stored at 4 °C. Genotype distribution of the IL-28B polymorphism at position −3176C/T (rs12979860) (LightMix Kit IL28B, Cat.-No. 40-0588-32 TIB MOLBIOL, Berlin, Germany) was detected by real time PCR (Roche Diagnostics, Manheim, Germany). Thirty of the patients with CHB received peg IFN-α treatment. There were no significant difference between groups by means of age, gender and IL28B rs12979860 polymorphism (p = 0.122, p = 0.07, p = 0.376 respectively). Patients with chronic hepatitis were categorized as grade and stage (minimal, moderate and severe) and then were analyzed for the polymorphism. There was no effect of IL28B −3176 C/T polymorphism on severity of illness (p = 0.293 for grade, p = 0.911 for stage). When the CHB treatment monitored in different time arrivals (beginning, 3th, 6th and 12th months of the treatment) in order to see if there was an effect on virological and biological response none of the genotypes of IL28B −3176C/T polymorphism altered peg IFN or oral antiviral treatment process. There are conflicting results about the role of IL28B rs12979860 polymorphism in CHB in the literature. In this preliminary study, we observed that IL28B rs12979860 polymorphism was not related with severity of illness and also was not effective on treatment response.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sheppard P, Kindsvogel W, Xu W et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4:63–68
Marcello T, Grakoui A, Barba-Spaeth G et al (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131:1887–1898
Ge D, Fellay J, Thompson AJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401
Rauch A, Kutalik Z, Descombes P et al (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338–1345
Suppiah V, Moldovan M, Ahlenstiel G et al (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100–1104
Tanaka Y, Nishida N, Sugiyama M et al (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105–1109
Tillmann HL, Thompson AJ, Patel K et al (2010) A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139:1586–1592
Martin MP, Qi Y, Goedert JJ et al (2010) IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV Infection. JID 202:1749–1753
Ihsak K et al (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696–699
Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, Wang JY (2012) IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens 79:302–305
Li W, Jiang Y, Jin Q et al (2011) Expression and gene polymorphisims of interleukin 28B and hepatitis B virus infection in Chinese Han population. Liver Int 31:1118–1126
Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S (2007) Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 126:245–249
Pagliaccetti NE, Chu EN, Bolen CR, Kleinstein SH, Robek MD (2010) Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology 401:197–206
Sonneveld MJ, Wong VW, Woltman AM et al (2012) Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 142:513–520
Tillmann HL, Yu MW (2011) IL28B: relevance extended to hepatitis B virus or limited to interferon-based therapies in hepatitis C virus? Liver Int 31:1068–1070
Takkenberg B, de Niet A, Benayed R, et al. Association between treatment outcome and rs12979860 polymorphism in HBeAg positive and negative chronic hepatitis B patients treated with Peginterferon alfa-2a (Pegasys) and Adefovir (Hepsera); An interim analysis. Presented as late breaker at the 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD 2010). Boston, October 29–November 2, 2010. http://trs.scivee.tv/node/2651
Lütgehetmann M, Bornscheuer T, Volz T et al (2011) Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology 140:2074–2083
Marcello T, Grakoui A, Barba-Spaeth G et al (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131:1887–1898
Morrow MP, Pankhong P, Laddy DJ et al (2009) Comparative ability of IL- 12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113:5868–5877
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kandemir, Ö., Fidancı, Ş.B., Demir, N. et al. Chronic hepatitis B and IL28B rs12979860 polymorphism: preliminary study. Mol Biol Rep 40, 6189–6194 (2013). https://doi.org/10.1007/s11033-013-2730-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-013-2730-0